Projet BOOSTER wins 9M€ grant from the program ‘RHU de l’Agence Nationale de la Recherche’

7/4/2019 - Networks

Pilotted by Professor Mikael Mazighi (Fondation A. de Rothschild and Hôpital Lariboisière), the consortium BOOSTER received 5 years of additional funding to continue developing personalized medicine for strokes in emergency situations.

Pilotted by Professor Mikael Mazighi (Fondation A. de Rothschild and Hôpital Lariboisière), the consortium BOOSTER received 5 years of additional funding at a total of 9,871,428€ to continue developing personalized medicine for strokes in emergency situations.

BOOSTER is a precision medicine that can be implemented anywhere (through simple blood work and brain imaging) and which aims to provide faster and better emergency care to a larger number of stroke victims. Ultimately resulting in an improved prognostic all while reducing the socio-economic cost of this condition. Booster thus represents a unique opportunity to transform stroke patient intake and contribute to the pioneering efforts of French hospital and university research.

BOOSTER (Brain clOt persOnalized therapeutic Strategies for sTroke Emergent Reperfusion) is a consortium focused on transforming the intake/acute management of stroke victims within the next 5 years. Strokes are a major public health issue: they are the primary cause of handicaps and the second leading cause of death. Each year more than 150,000 people are impacted. This is one stroke every 4 minutes. Strokes provoked by cerebral artery occlusions are the most pervasive causes of death and handicap. In this type of urgent care, treatment which is only available to a minority of patients involves the perfusion of a medication which dissolves the clot (the thrombolysis) and an intervention which captures the clot (the thrombectomy). The efficacy of this treatment remains limited and results in an increased risk of cerebral hemorrhage.